The original disclosure in Japanese was released on January 24, 2022 at 15:00 (GMT +8)

January 24, 2022
CompanyHeadquarters
RepresentativeContact
TelephoneWebsite

Takara Bio Inc. (First Section TSE, code: 4974)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, Head ofCorporate Management Division(+81)77-565-6970
https://www.takara-bio.co.jp/

Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization
Takara Bio Inc. (the “Company”) hereby announces the recording of extraordinary gains and losses related tosubsidy grants during the nine months of the fiscal year ending March 31, 2022 (April 1, 2021 – December 31,2021).

1. Details of Extraordinary Gains and Losses
The Company is participating in the Ministry of Health, Labour and Welfare’s “Project for Emergency
Development of Vaccines Production Systems in Fiscal 2020” and promoting the development of manufacturing
facilities through subsidies.*
In the cumulative period of the third quarter of the fiscal year under review, an extraordinary gain of 3,205
million yen associated with the subsidies will be recorded. Along with that, an extraordinary loss of the sameamount (loss on reduction of non-current assets) will be recorded by reducing the value of the subject assets.
* News Release (August 7, 2020)[Japanese text only]

https://ir.takara-bio.co.jp/ja/news_all/news_Release/newsr_2014365k238m7014115_200807.html
2. Impact on the Consolidated Financial Results
The impact of the extraordinary gains and losses has already been reflected in the forecast for the fiscal year
ending March 31, 2022 (released on November 9, 2021) so there is no revision of the forecast. The Company
will promptly disclose any impact on the business performance due to the progress made in the future and otherfactors.
(Reference) Consolidated financial results forecasts for the current fiscal year (released on November 9, 2021)
and actual consolidated results for the previous fiscal year
(Millions of yen)
Net sales

Operating

Ordinary

profitprofit

Net income
attributable toowners of the parent

Consolidated financial results forecasts forthe current fiscal year

59,30020,00020,20014,10046,086

13,952

14,159

9,547(Fiscal year ending March 31, 2022)
Actual consolidated results for the previous
fiscal year
(Fiscal year ended March 31, 2021)

The original disclosure in Japanese was released on January 24, 2022 at 15:00 (GMT +8)

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies andbeliefs that are not historical facts are forward-looking statements about the further performance of theCompany and its consolidated subsidiaries. These statements are based on management’s assumptions andbeliefs in light of information currently available to it, but are based on a number of assumptions and beliefsderived from information that contains significant risks and uncertainties. Actual results may differ materiallyfrom these forecasts due to various factors. Factors that could influence actual results include, but are notlimited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations,changes in laws and government systems, pressure from competitors’ prices and product strategies, declines inselling power of the Company’s existing and new products, disruptions to production, violations of ourintellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.